Logo image of ALGS

ALIGOS THERAPEUTICS INC (ALGS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALGS - US01626L2043 - Common Stock

9.99 USD
-0.1 (-0.99%)
Last: 12/5/2025, 8:02:47 PM
Fundamental Rating

2

Overall ALGS gets a fundamental rating of 2 out of 10. We evaluated ALGS against 531 industry peers in the Biotechnology industry. ALGS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ALGS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALGS has reported negative net income.
In the past year ALGS has reported a negative cash flow from operations.
In the past 5 years ALGS always reported negative net income.
ALGS had a negative operating cash flow in each of the past 5 years.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ALGS has a worse Return On Assets (-78.77%) than 66.54% of its industry peers.
With a Return On Equity value of -120.37%, ALGS perfoms like the industry average, outperforming 40.75% of the companies in the same industry.
Industry RankSector Rank
ROA -78.77%
ROE -120.37%
ROIC N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

ALGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALGS has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ALGS has been reduced compared to 5 years ago.
ALGS has a worse debt/assets ratio than last year.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -8.53, we must say that ALGS is in the distress zone and has some risk of bankruptcy.
ALGS has a worse Altman-Z score (-8.53) than 70.84% of its industry peers.
ALGS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALGS (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.53
ROIC/WACCN/A
WACC8.76%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.70 indicates that ALGS has no problem at all paying its short term obligations.
With a Current ratio value of 4.70, ALGS perfoms like the industry average, outperforming 53.08% of the companies in the same industry.
A Quick Ratio of 4.70 indicates that ALGS has no problem at all paying its short term obligations.
The Quick ratio of ALGS (4.70) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.7
Quick Ratio 4.7
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ALGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.04%, which is quite impressive.
ALGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.88%.
Measured over the past years, ALGS shows a decrease in Revenue. The Revenue has been decreasing by -3.28% on average per year.
EPS 1Y (TTM)24.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.98%
Revenue 1Y (TTM)-55.88%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-41.61%

3.2 Future

Based on estimates for the next years, ALGS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.34% on average per year.
The Revenue is expected to grow by 119.76% on average over the next years. This is a very strong growth
EPS Next Y25.43%
EPS Next 2Y15.58%
EPS Next 3Y11.33%
EPS Next 5Y20.34%
Revenue Next Year-28.43%
Revenue Next 2Y-24.66%
Revenue Next 3Y-24.16%
Revenue Next 5Y119.76%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.58%
EPS Next 3Y11.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (12/5/2025, 8:02:47 PM)

9.99

-0.1 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners49.59%
Inst Owner Change-2.04%
Ins Owners2.13%
Ins Owner Change0%
Market Cap61.44M
Revenue(TTM)2.65M
Net Income(TTM)-86.46M
Analysts84
Price Target81.86 (719.42%)
Short Float %4.87%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.17%
Min EPS beat(2)-56.86%
Max EPS beat(2)36.53%
EPS beat(4)2
Avg EPS beat(4)-6.95%
Min EPS beat(4)-56.86%
Max EPS beat(4)36.53%
EPS beat(8)4
Avg EPS beat(8)7.35%
EPS beat(12)6
Avg EPS beat(12)6.33%
EPS beat(16)8
Avg EPS beat(16)7.12%
Revenue beat(2)2
Avg Revenue beat(2)81.81%
Min Revenue beat(2)45.29%
Max Revenue beat(2)118.33%
Revenue beat(4)3
Avg Revenue beat(4)49.35%
Min Revenue beat(4)-8.53%
Max Revenue beat(4)118.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.76%
PT rev (3m)0%
EPS NQ rev (1m)20.83%
EPS NQ rev (3m)20.83%
EPS NY rev (1m)-3.64%
EPS NY rev (3m)4.98%
Revenue NQ rev (1m)20%
Revenue NQ rev (3m)20%
Revenue NY rev (1m)1.79%
Revenue NY rev (3m)21.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.22
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-10.08
EYN/A
EPS(NY)-7.42
Fwd EYN/A
FCF(TTM)-12.93
FCFYN/A
OCF(TTM)-12.87
OCFYN/A
SpS0.43
BVpS11.68
TBVpS11.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.77%
ROE -120.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.81%
Cap/Sales 14.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.7
Quick Ratio 4.7
Altman-Z -8.53
F-Score4
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)18.19%
Cap/Depr(5y)31.84%
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.98%
EPS Next Y25.43%
EPS Next 2Y15.58%
EPS Next 3Y11.33%
EPS Next 5Y20.34%
Revenue 1Y (TTM)-55.88%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-41.61%
Revenue Next Year-28.43%
Revenue Next 2Y-24.66%
Revenue Next 3Y-24.16%
Revenue Next 5Y119.76%
EBIT growth 1Y12.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.43%
EBIT Next 3Y-8.8%
EBIT Next 5Y-12.52%
FCF growth 1Y-8.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.26%
OCF growth 3YN/A
OCF growth 5YN/A

ALIGOS THERAPEUTICS INC / ALGS FAQ

Can you provide the ChartMill fundamental rating for ALIGOS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALGS.


Can you provide the valuation status for ALIGOS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ALIGOS THERAPEUTICS INC (ALGS). This can be considered as Overvalued.


How profitable is ALIGOS THERAPEUTICS INC (ALGS) stock?

ALIGOS THERAPEUTICS INC (ALGS) has a profitability rating of 0 / 10.